0000905718-21-000673.txt : 20210513
0000905718-21-000673.hdr.sgml : 20210513
20210513192858
ACCESSION NUMBER: 0000905718-21-000673
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210513
FILED AS OF DATE: 20210513
DATE AS OF CHANGE: 20210513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abingworth LLP
CENTRAL INDEX KEY: 0001397144
STATE OF INCORPORATION: X0
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40407
FILM NUMBER: 21921404
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 (0)20 7534 1500
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001831828
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 812744449
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY
STREET 2: 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-770-0077
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY
STREET 2: 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
3
1
vera_fm3may132021.xml
X0206
3
2021-05-13
0
0001831828
Vera Therapeutics, Inc.
VERA
0001397144
Abingworth LLP
38 JERMYN STREET
LONDON
X0
SW1Y 6DN
UNITED KINGDOM
0
0
1
0
Series C Preferred Stock
Class A Common Stock
2187504
I
See Footnote
The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.
The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ John Heard
2021-05-13